AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|AAPL299.11+2.10 (+0.71%) ▲|ABBV234.85+4.84 (+2.10%) ▲|ABT90.75+2.92 (+3.32%) ▲|ACN126.82+1.99 (+1.59%) ▲|ADBE199.47+4.57 (+2.34%) ▲|AMAT586.25-53.93 (-8.42%) ▼|AMD520.90-30.73 (-5.57%) ▼|AMGN347.78+3.06 (+0.89%) ▲|AMT178.42+1.99 (+1.13%) ▲|AMZN234.44+1.65 (+0.71%) ▲|AVGO383.75-8.39 (-2.14%) ▼|AXP337.06-1.01 (-0.30%) ▼|BA218.49-2.34 (-1.06%) ▼|BAC57.79+0.42 (+0.72%) ▲|BKNG169.51+1.74 (+1.04%) ▲|BLK1,020.11-31.64 (-3.01%) ▼|BMY55.68+0.98 (+1.79%) ▲|BNY147.89+1.45 (+0.99%) ▲|BRK-B493.60+4.91 (+1.00%) ▲|C145.37-0.30 (-0.21%) ▼|CAT989.58-32.71 (-3.20%) ▼|CL91.38+2.71 (+3.05%) ▲|CMCSA22.89+0.57 (+2.53%) ▲|COF198.39-2.31 (-1.15%) ▼|COP110.28+0.58 (+0.52%) ▲|COST961.01+9.66 (+1.02%) ▲|CRM154.87+4.75 (+3.16%) ▲|CSCO121.81+0.28 (+0.23%) ▲|CVS101.33+0.03 (+0.03%) ▲|CVX176.14+1.08 (+0.61%) ▲|DE598.59+0.00 (+0.00%) ▲|DHR178.54+0.35 (+0.20%) ▲|DIS103.44+0.99 (+0.96%) ▲|DUK125.06+1.54 (+1.25%) ▲|EMR144.51-5.71 (-3.80%) ▼|FDX323.30-5.48 (-1.67%) ▼|GD349.10+5.74 (+1.67%) ▲|GE357.08+1.96 (+0.55%) ▲|GEV1,048.85-78.74 (-6.98%) ▼|GILD125.78+0.91 (+0.73%) ▲|GM80.08-0.35 (-0.44%) ▼|GOOG346.84-1.95 (-0.56%) ▼|GOOGL347.35-2.21 (-0.63%) ▼|GS1,099.08-7.29 (-0.66%) ▼|HD325.50-1.13 (-0.34%) ▼|HON224.66-3.46 (-1.51%) ▼|IBM265.84+13.62 (+5.40%) ▲|INTC133.70-7.24 (-5.14%) ▼|INTU260.76+2.99 (+1.16%) ▲|ISRG401.54-1.42 (-0.35%) ▼|JNJ237.14+5.85 (+2.53%) ▲|JPM334.13+2.65 (+0.80%) ▲|KO79.93+0.40 (+0.50%) ▲|LIN517.00+0.29 (+0.06%) ▲|LLY1,104.37+2.29 (+0.21%) ▲|LMT502.25+8.65 (+1.75%) ▲|LOW214.90+0.50 (+0.23%) ▲|LRCX370.97-38.57 (-9.42%) ▼|MA488.32+4.23 (+0.87%) ▲|MCD271.75+1.65 (+0.61%) ▲|MDLZ60.66+1.15 (+1.92%) ▲|MDT80.36+1.09 (+1.38%) ▲|META564.45+0.60 (+0.11%) ▲|MMM162.40-0.82 (-0.50%) ▼|MO71.12+1.61 (+2.32%) ▲|MRK118.74+3.26 (+2.82%) ▲|MS227.48+0.39 (+0.17%) ▲|MSFT372.72+5.38 (+1.46%) ▲|MU1,072.68-138.70 (-11.45%) ▼|NEE86.58+0.50 (+0.58%) ▲|NFLX73.19+0.31 (+0.42%) ▲|NKE42.94-0.25 (-0.58%) ▼|NOW97.36+4.35 (+4.67%) ▲|NVDA201.83-6.82 (-3.27%) ▼|ORCL168.27-6.80 (-3.88%) ▼|PEP141.06+0.35 (+0.25%) ▲|PFE25.01-0.08 (-0.30%) ▼|PG150.60+2.92 (+1.98%) ▲|PLTR118.86-0.64 (-0.54%) ▼|PM177.91+4.74 (+2.74%) ▲|QCOM201.15-20.75 (-9.35%) ▼|RTX184.92+3.09 (+1.70%) ▲|SBUX100.89+0.74 (+0.74%) ▲|SCHW93.03+1.00 (+1.09%) ▲|SO94.60+1.17 (+1.25%) ▲|SPG216.71+2.14 (+1.00%) ▲|T22.87+0.77 (+3.48%) ▲|TMO466.82+2.81 (+0.61%) ▲|TMUS183.26+3.20 (+1.78%) ▲|TSLA384.06-20.99 (-5.18%) ▼|TXN302.80-29.48 (-8.87%) ▼|UBER70.55-0.88 (-1.23%) ▼|UNH407.91+1.23 (+0.30%) ▲|UNP260.49+0.58 (+0.22%) ▲|UPS106.18-1.06 (-0.99%) ▼|USB59.74+1.06 (+1.81%) ▲|V331.10+4.50 (+1.38%) ▲|VZ46.60+1.24 (+2.73%) ▲|WFC83.83-0.01 (-0.01%) ▼|WMT119.53+2.35 (+2.01%) ▲|XOM140.15+1.68 (+1.21%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: medicines

newssourceFORcompanyinformationcontent1marketreleases

Result of General Meeting

June 11, 2025

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.

Insmed Announces Proposed $650 Million Public Offering of Common Stock

BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

Elysium Therapeutics’ Investor Webcast Highlights “Fentanyl Rebound” as Key Challenge in Reducing Opioid Overdose Hospitalizations and Deaths

Elysium's Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology designed specifically to combat oral fentanyl overdose LYONS, Colo., June 11, 2025 /PRNewswire/ -- Elysium Therapeutics,...

ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025

ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025

BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis

Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients...

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline Results – Paradigm Shift in Surgical Infection Prevention

PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future 
PESG issues a new briefing following PolyPid’s clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid’s D-PLEX100 as Potential New Standard of Care in the Future

“STRONGER TOGETHER”: SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION”, ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON...

Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth...

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF)...

EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

Financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support...

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children

Press release

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

June 11, 2025, 12:01 AM CET

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers